Here are the DEF 14A proxy statements from Citius Oncology, Inc. (CTOR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CTOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTOR filings page.
Citius Oncology, Inc. (CTOR) is calling its 2026 Annual Meeting of Stockholders for September 29, 2026 at its Cranford, New Jersey headquarters. Holders of 92,981,204 common shares as of August 17, 2026 may vote.
Stockholders will vote on electing three Class II directors (Dr. Eugene Holuka, Robert Smith and Carol Webb) to terms expiring at the 2029 annual meeting, and on ratifying Wolf & Company, P.C. as auditor for the fiscal year ending September 30, 2026. Directors are elected by plurality; the auditor ratification requires a majority of votes represented and entitled to vote.
The nine‑member board is classified into three classes and a majority, including all committee members, is independent; Leonard Mazur (Chairman and CEO) and Myron Holubiak (Secretary and Executive Vice Chairman) are not independent. Citius Pharmaceuticals, Inc. owns 66,049,615 shares, or 71.0%, and also provides shared services under an agreement with a quarterly fee of about $940,000. Executive compensation relies on salary and equity awards, with a clawback policy, insider trading policy, and emerging‑growth‑company scaled disclosure.